

Abaloparatide for osteoporosis

- [Improving High-Risk Osteoporosis Medication Adherence and Safety With an Automated Dashboard](#)
- [Compliance With Parathyroid Hormone Analog Medications at a Single Osteoporosis Treatment Center](#)
- [Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis](#)
- [Male Osteoporosis: A Comprehensive Review of Treatment Approaches in Modern Pharmacotherapy and Traditional Chinese Medicine Interventions](#)
- [The Chronobiology of Hormone Administration: "Doctor, what time should I take my medication?"](#)
- [Clinical efficacy of osteoporosis treatments](#)
- [Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide](#)
- [An oral robotic pill reliably and safely delivers teriparatide with high bioavailability in healthy volunteers: A phase 1 study](#)

see [Osteoporosis treatment](#).

(TymlosTM):

a [recombinant DNA](#) copy of the entire human [parathyroid hormone](#).

Rx: 80 micrograms SQ daily. Lifetime treatment limit of all parathyroid analogs total: 2 years

[Abaloparatide](#) increases [bone formation](#) for treating established [osteoporosis](#).

Initial treatment with abaloparatide may result in greater [vertebral fracture](#) reduction compared with [alendronate](#) in postmenopausal women with [osteoporosis](#) ¹⁾.

Sequential therapy using ABL/[alendronate](#) (ALN) may be cost [effective](#) compared with generic ALN monotherapy in US men aged ≥ 50 years at high fracture risk, especially in those aged ≥ 60 years. Unbranded teriparatide (TPTD)/ALN and no treatment were dominated interventions (less QALY, more costs) compared with ABL/ALN or ALN monotherapy ²⁾

Have not yet been studied in the chronic [glucocorticoid](#) population ³⁾.

¹⁾

Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS. Effect of Abaloparatide Versus Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis. J Clin Endocrinol Metab. 2019 Nov 1. pii: dgz162. doi: 10.1210/clinem/dgz162. [Epub ahead of print] PubMed PMID: 31674644.

²⁾

Hiligsmann M, Silverman SS, Singer AJ, Pearman L, Mathew J, Wang Y, Caminis J, Reginster JY. Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States. Pharmacoeconomics. 2023 Apr 22. doi: 10.1007/s40273-023-01270-x. Epub ahead of print.

PMID: 37086385.

³⁾

Taylor AD, Saag KG. Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy. Core Evid. 2019 Aug 23;14:41-50. doi: 10.2147/CE.S172820. eCollection 2019. PubMed PMID: 31692480; PubMed Central PMCID: PMC6711555.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

https://neurosurgerywiki.com/wiki/doku.php?id=abaloparatide_for_osteoporosis

Last update: **2024/06/07 02:49**

